Literature DB >> 18806625

Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors.

Sebastien Faure1, Annabelle Bureau, Nicole Oudart, James Javellaud, Albert Fournier, Jean-Michel Achard.   

Abstract

OBJECTIVES: The contribution of the AT2 and AT4 angiotensin receptors to the protective role of the AT1 receptor blocker candesartan in acute ischemic stroke was investigated.
METHODS: Embolic stroke was induced by injection of calibrated microspheres (50 microm) in the right internal carotid in Sprague-Dawley rats.
RESULTS: Inhibition of production of endogenous angiotensins by pretreatment for 24 h with lisinopril significantly increased mortality and infarct volume, whereas candesartan for 24 h reduced blood pressure to the same extent but had no deleterious effect. A more sustained pretreatment with candesartan for 5 days significantly decreased mortality, neurological deficit and infarct size. The AT2 receptor antagonist PD123319 and the AT4 receptor antagonist divalinal abolished the protective effect of 5 days' AT1 blockade. Combined blockade of AT2 and AT4 in candesartan pretreated rats resulted in an increased mortality, neurological deficit and infarct volume of similar magnitude to lisinopril pretreatment. Coadministration of lisinopril 24 h before surgery completely blunted the protective effect of candesartan pretreatment. Administration of exogenous angiotensin IV (1 nmol) reversed the deleterious effect of lisinopril pretreatment.
CONCLUSION: Protection against acute cerebral ischemia induced by AT1 blockade for 5 days is blood pressure independent and mediated by both AT2 and AT4 angiotensin receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806625     DOI: 10.1097/HJH.0b013e32830dd5ee

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  19 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats.

Authors:  Claudia A McCarthy; Antony Vinh; Alyson A Miller; Anders Hallberg; Mathias Alterman; Jennifer K Callaway; Robert E Widdop
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

Review 3.  The role of angiotensin II receptors in stroke protection.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

4.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

5.  Angiotensin II Receptor Blockers Attenuate Lipopolysaccharide-Induced Memory Impairment by Modulation of NF-κB-Mediated BDNF/CREB Expression and Apoptosis in Spontaneously Hypertensive Rats.

Authors:  Ruby Goel; Shahnawaz Ali Bhat; Kashif Hanif; Chandishwar Nath; Rakesh Shukla
Journal:  Mol Neurobiol       Date:  2017-02-18       Impact factor: 5.590

6.  Candesartan improves ischemia-induced impairment of the blood-brain barrier in vitro.

Authors:  Gohei So; Shinsuke Nakagawa; Yoichi Morofuji; Takeshi Hiu; Kentaro Hayashi; Kunihiko Tanaka; Kazuhiko Suyama; Maria A Deli; Izumi Nagata; Takayuki Matsuo; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2014-12-30       Impact factor: 5.046

Review 7.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

8.  Angiotensin-converting enzyme 2: a new target for neurogenic hypertension.

Authors:  Yumei Feng; Huijing Xia; Robson A Santos; Robert Speth; Eric Lazartigues
Journal:  Exp Physiol       Date:  2009-11-18       Impact factor: 2.969

9.  AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

Authors:  Ahmed Alhusban; Anna Kozak; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

10.  Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.

Authors:  Adam P Mecca; Timothy E O'Connor; Michael J Katovich; Colin Sumners
Journal:  Exp Physiol       Date:  2009-05-08       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.